These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 19402802)

  • 41. Pharmaceuticals issue brief: generic and therapeutic substitution: year end report--2004.
    Health Policy Tracking Service staff
    Issue Brief Health Policy Track Serv; 2004 Dec; ():1-14. PubMed ID: 15724310
    [No Abstract]   [Full Text] [Related]  

  • 42. Informed by the European Union experience: what the United States can anticipate and learn from the European Union's regulatory approach to biosimilars.
    Gitter DM
    Seton Hall Law Rev; 2011; 41(2):559-92. PubMed ID: 21739759
    [No Abstract]   [Full Text] [Related]  

  • 43. A generic drug primer: regulatory aspects and scientific concepts.
    Henderson JD; White GL
    Mil Med; 1998 Apr; 163(4):193-7. PubMed ID: 9575760
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012.
    Kay J; Feagan BG; Guirguis MS; Keystone EC; Klein AV; Lubiniecki AS; Mould DR; Nyarko KA; Ridgway AA; Trudeau ME; Wang J
    Biologicals; 2012 Nov; 40(6):517-27. PubMed ID: 23084808
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The constitutional protection of trade secrets and patents under the Biologics Price Competition and Innovation Act of 2009.
    Epstein RA
    Food Drug Law J; 2011; 66(3):285-328. PubMed ID: 24505851
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The challenge of indication extrapolation for infliximab biosimilars.
    Feagan BG; Choquette D; Ghosh S; Gladman DD; Ho V; Meibohm B; Zou G; Xu Z; Shankar G; Sealey DC; Russell AS
    Biologicals; 2014 Jul; 42(4):177-83. PubMed ID: 24962198
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biosimilars: biologics that meet patients' needs and healthcare economics.
    McCamish M; Yoon W; McKay J
    Am J Manag Care; 2016 Sep; 22(13 Suppl):S439-S442. PubMed ID: 28719221
    [TBL] [Abstract][Full Text] [Related]  

  • 48. US drug regulator warns manufacturers that it will not accept data from Indian research center.
    Dyer O
    BMJ; 2016 Apr; 353():i2476. PubMed ID: 27130404
    [No Abstract]   [Full Text] [Related]  

  • 49. Review on the worldwide regulatory framework for biosimilars focusing on the Mexican case as an emerging market in Latin America.
    Ibarra-Cabrera R; Mena-Pérez SC; Bondani-Guasti A; García-Arrazola R
    Biotechnol Adv; 2013 Dec; 31(8):1333-43. PubMed ID: 23714280
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Understanding State Regulation of Biosimilars and Effect on Prescribers.
    Yale K; Awosika O; Rengifo-Pardo M; Ehrlich A
    J Drugs Dermatol; 2017 Oct; 16(10):995-1000. PubMed ID: 29036253
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharma allowed to make own genetics.
    Owens J
    Nat Rev Drug Discov; 2005 Jul; 4(7):530. PubMed ID: 16075483
    [No Abstract]   [Full Text] [Related]  

  • 52. Pharmacovigilance and biosimilars: considerations, needs and challenges.
    Casadevall N; Edwards IR; Felix T; Graze PR; Litten JB; Strober BE; Warnock DG
    Expert Opin Biol Ther; 2013 Jul; 13(7):1039-47. PubMed ID: 23527621
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
    Jelkmann W
    Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Progress and Hurdles for Follow-on Biologics.
    Sarpatwari A; Avorn J; Kesselheim AS
    N Engl J Med; 2015 Jun; 372(25):2380-2. PubMed ID: 25946143
    [No Abstract]   [Full Text] [Related]  

  • 55. Hot Topics in Primary Care: Demystifying the Differences: Follow-on Biologics, Biosimilars, and Generics.
    Wright EE; Blevins TC; Reed B; Pollom RD
    J Fam Pract; 2017 Apr; 66(4 Suppl):S22-S27. PubMed ID: 28375404
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Impact of Pharmaceutical Excipients on Oral Drug Absorption: A Focus on Intestinal Drug Transporters.
    Zou L; Ni Z; Tsakalozou E; Giacomini KM
    Clin Pharmacol Ther; 2019 Feb; 105(2):323-325. PubMed ID: 30663035
    [No Abstract]   [Full Text] [Related]  

  • 57. Pharmaceuticals and Medical Devices: Cost Savings.
    Steiner DJ;
    Issue Brief Health Policy Track Serv; 2016 Dec; 2016():1-31. PubMed ID: 28252884
    [No Abstract]   [Full Text] [Related]  

  • 58. Biosimilars in Dermatology: Current Situation (Part I).
    Puig L; Carretero G; Daudén E; Ferrándiz C; Marrón SE; Martorell A; Pérez-Suárez B; Rodriguez-Cerdeira C; Ruiz-Villaverde R; Sánchez-Carazo JL; Velasco M;
    Actas Dermosifiliogr; 2015 Sep; 106(7):545-9. PubMed ID: 25987472
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.
    Grabowski HG; Kyle M; Mortimer R; Long G; Kirson N
    Health Aff (Millwood); 2011 Nov; 30(11):2157-66. PubMed ID: 22068409
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Pharmaceuticals: the banning of "tested" generic drugs from India; the first 3D tablet].
    Nau JY
    Rev Med Suisse; 2015 Aug; 11(482):1506-7. PubMed ID: 26449106
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.